Imaging Endpoints congratulates Anthony G. Letai, MD, PhD.

Imaging Endpoints congratulates Anthony G. Letai, MD, PhD, on his well-deserved appointment as the 18th Director of the National Cancer Institute (NCI). Dr. Letai was sworn in on September 29, 2025, by Health and Human Services Secretary Robert F. Kennedy, Jr.  Dr. Letai joins NCI after service as a professor of medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute. His research has centered on cell death in cancer, hematologic malignancies, treatment development, and predictive biomarkers.

Imaging Endpoints is proud to have collaborated with Dr. Letai for many years in hematology trials aimed at advancing novel immunotherapies for patients worldwide, including the approval of landmark therapies – the first CAR T-cell therapy for mantle cell lymphoma and a novel therapy for large B-cell lymphoma. We congratulate Dr. Letai and wish him great success in leading the world’s largest and most prestigious cancer research agency.